FDA Approved: LIRAGLUTIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

View source ↗

Summary

FDA approved Teva's supplemental application for liraglutide (NDA 022341), updating labeling and/or indications for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• liraglutide (liraglutide)

Snippet

SUPPL AP for LIRAGLUTIDE (LIRAGLUTIDE)